Secondary prevention leader Berkeley HeartLab specializes in secondary prevention for cardiovascular disease, presenting upsell opportunities to clinics and hospitals seeking advanced monitoring tools beyond primary screening.

Proprietary testing edge Unique segmented gradient gel electrophoresis and genetic testing capabilities create a differentiator, offering potential cross-sell of high-value lipid and genetic risk assessments to cardiology and primary care networks.

CLIA‑certified capacity Large-volume, high-complexity laboratory operations with the ability to handle over 35 diagnostic tests positions Berkeley HeartLab as a scalable partner for payer networks and diagnostic partnerships.

Reimbursement viability Tests are described as reimburseable by private insurance and Medicare, suggesting sales opportunities with healthcare systems and payer strategies to expand covered services.

Financial robustness With revenue in the range of tens of millions, there is a credible platform for channel partnerships, channel expansion, and co-marketing with larger lab and diagnostics players in the ecosystem.